Drugmaker shares drop after RFK Jr. tapped to lead HHS
- Shares in vaccine makers and healthcare firms dropped sharply after Robert F Kennedy Jr was tapped as US Health Secretary, raising investor concerns about the sector.
- Kennedy has stated he will use the position to crack down on 'Big Pharma,' which has led to fears of increased anti-vaccine rhetoric.
- Health policy experts believe this could deter Americans from receiving Covid shots and routine immunizations, as noted by former CDC Director Dr. Richard Besser.
17 Articles
17 Articles
Lurie Children's doctors worry about vaccine disinformation as Trump taps RFK Jr. for HHS secretary
Doctors may have to reeducate families on flu and COVID vaccine effectiveness if Robert F. Kennedy is confirmed as Health and Human Services secretary
Drugmaker Stocks Slide as Trump Taps Vaccine Skeptic RFK Jr for US Health Job
US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. Track elected officials, research health conditions, and find news you can use in politics, business, health, and education.
Vaccine-maker stocks like Moderna, Pfizer drop as Trump taps RFK Jr. to lead HHS
Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and former presidential hopeful Robert F. Kennedy Jr. as his pick to lead the U.S. Department of Health and Human Services.
Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job
Shares of major U.S. drugmakers fell on Friday after President-elect Donald Trump picked anti-vaccine activist Robert F. Kennedy Jr. to head the Department of Health and Human Services, the top U.S. health agency.
Coverage Details
Bias Distribution
- 43% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium













